Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with GP Neoadjuvant Therapy for Locoregionally Advanced NPC
NCT04833257Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2021
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Apr 2021; status: completed.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04833257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833257.